We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.

How Effective Is Bevacizumab for Ovarian Cancer?

By Cindy Quarters
Updated May 17, 2024
Our promise to you
WiseGeek is dedicated to creating trustworthy, high-quality content that always prioritizes transparency, integrity, and inclusivity above all else. Our ensure that our content creation and review process includes rigorous fact-checking, evidence-based, and continual updates to ensure accuracy and reliability.

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

Editorial Standards

At WiseGeek, we are committed to creating content that you can trust. Our editorial process is designed to ensure that every piece of content we publish is accurate, reliable, and informative.

Our team of experienced writers and editors follows a strict set of guidelines to ensure the highest quality content. We conduct thorough research, fact-check all information, and rely on credible sources to back up our claims. Our content is reviewed by subject-matter experts to ensure accuracy and clarity.

We believe in transparency and maintain editorial independence from our advertisers. Our team does not receive direct compensation from advertisers, allowing us to create unbiased content that prioritizes your interests.

Bevacizumab, brand name Avastin®, is a drug that is used to treat certain kinds of cancers, including ovarian cancer and breast cancer. It is an antiangiogenic medicine, which means that it works by stopping or reducing the creation of blood vessels. This prevents the growth of tumors by denying them the blood they need in order to grow. The drug has gained approval in the U.S. for use in treating several types of cancer, but as of 2011 ovarian cancer is not among those treated in this way.

In a U.S. clinical trial it was found that using bevacizumab for ovarian cancer during chemotherapy and for a full year afterward stopped the growth of the cancer for an average of less than four months. A study based on the results of the trial concluded that Avastin® is not cost-effective as a therapy for primary ovarian cancer. The study concluded that the drug's limited benefit provided did not justify the high cost involved. A report recommending against the use of this medicine for ovarian cancer was made to the European Society of Clinical Oncology in the fall of 2010 based on a separate trial with similar results.

If the cancer is a result of metastasis from primary colon or rectal cancer, however, then using bevacizumab for ovarian cancer has been shown to have better results. A secondary or metastatic cancer has the same type of cancer cells as the primary location. This means that using bevacizumab for ovarian cancer that started in the colon produces different results than it does on primary ovarian cancer, since the secondary cancer cells have different characteristics.

There are other concerns about using bevacizumab for ovarian cancer. A report made to the Society of Gynecologic Oncologists in 2010 indicated that the drug doubled the risk of gastrointestinal complications such as perforations and hemorrhages. The women in the study had just been diagnosed and were treated with Avastin® as well as other types of chemotherapy. Risk level was increased even more for women with a history of significant problems with their bowels.

Ultimately, using this drug can be of some help, but it is not likely to be used very often. Patients should understand not only the cost factors, but also the level of risk involved with using Avastin®, in order to make an informed decision. This drug is considered best used only on secondary ovarian cancer, where it may be applied with good results.

WiseGeek is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
Link to Sources
Discussion Comments
WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.